Venture Life Group - Licensing and distribution agreements
9th
VENTURE LIFE GROUP PLC
("Venture Life" "VLG" or the "Company")
License agreement secured of internally developed oral care asset
New exclusive long term international distribution agreements secured for Gelclair & Pomi-T
Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, is pleased to announce the licensing of an internally developed oral care range to an existing long term customer and that it has signed a further distribution agreements for Gelclair & Pomi-T.
Oral care asset
VLG has licensed a range of its own internally developed mouth ulcer products (the "Products") to a long term and existing customer for certain key EU and other markets. The Products were developed at VLG's facilities in
The total license fee to be received by VLG is
Gelclair
Further to the signing of Gelclair in
The Canadian partner is one of
The
Pomi-T
The Company has signed a long-term distribution agreement for Pomi-T in
Gianluca Braguti, Chief Manufacturing and Development Officer commented: "I am delighted to license these new products to an existing significant long term partner of the Group. We have a very innovative and active development team in Biokosmes, and this license transaction demonstrates the significant value this team creates for both ourselves and our customers".
Also, further to the acquisition of Gelclair last year, we are pleased to have appointed another two important new partners in both
For further information, please contact:
|
Venture Life Group PLC |
+44 (0) 1344 578004 |
||
|
|
|
||
|
Cenkos Securities plc (Nomad and Joint Broker) |
+44 (0) 20 7397 8900 |
||
|
|
|
||
|
Singer Capital markets (Joint Broker) |
+44 (0) 20 7496 3000 |
||
|
|
|
||
|
|
|
||
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the
Through its two Development & Manufacturing operations in
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).
Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.
Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.
All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.
This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.
Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.
This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.
FOR OUR FULL DISCLAIMER CLICK HERE